注塑吹塑成型
药瓶

1. 为什么 IBM 是韩国制药工艺标准

Injection blow molding has established itself as the process standard for Korean pharmaceutical primary packaging in HDPE and PP through the convergence of three process advantages that are uniquely relevant to Korean pharmaceutical production requirements. First, injection-moulded neck precision: IBM produces the bottle neck by injection moulding — the same precision manufacturing process that produces pharmaceutical closure components — achieving ±0.05 mm neck OD tolerance consistently across all cavities and all production cycles. This precision is the enabling capability for Korean pharmaceutical CRC containers, dropper-cap bottles and pump-dispenser primary containers, all of which require closure engagement at dimensional tolerances that extrusion blow molding cannot achieve without secondary neck processing. Second, zero flash and zero particulate generation: IBM produces no flash at any stage of the process, which means no trim station, no mechanical trimming operation, and no plastic particles generated in the production environment. For Korean pharmaceutical cleanroom production where particulate control is a GMP requirement, IBM’s inherent particle-free process is a direct regulatory compliance advantage over EBM. Third, multi-cavity efficiency: IBM’s 注塑吹塑机 平台在 10 毫升规格下可实现多达 30 个腔体——这种腔体数量使得韩国制药企业能够在单机规模上实现 EBM 在小规格下无法达到的经济效益。

韩国药品包装容器的生产还受到韩国特定监管要求的驱动。韩国食品药品安全部（KFDA）的药品包装容器法规要求提供容器资质文件，包括尺寸合规性、化学相容性、可萃取物和可浸出物数据以及密封功能测试——所有这些IBM包装容器均通过了既定的资质认证流程。由于这些法规和质量要求，韩国制药品牌、韩国合同制造商和韩国药品出口商均指定使用IBM包装容器作为其小规格药品初级包装。

2. 韩国食品药品安全部（KFDA）药品包装要求

韩国药品包装容器的要求由韩国食品药品安全部（KFDA）根据《韩国药品法》和《韩国药典》制定。韩国药品包装容器的要求与ICH Q6A规范和USP/EP塑料容器标准基本一致，但针对某些特定类型的容器规格增加了韩国特有的要求。韩国药品包装容器生产商在开始韩国药品认证流程之前，必须了解哪些KFDA要求适用于其特定的容器规格。

韩国KFDA塑料容器标准

韩国药典（KP）《药品用塑料容器通用专论》规定了高密度聚乙烯（HDPE）和聚丙烯（PP）药品容器的测试要求，包括：在水、4%乙酸、20%乙醇、庚烷和甲醇萃取介质中的萃取物含量低于KP限值；重金属含量低于1 ppm；苯酚含量低于5 ppm；紫外吸收值在限值范围内。工业包装容器（IBM容器）必须在规定的壁厚下，使用生产用HDPE或PP树脂（而非实验室测试样品）通过这些测试。韩国药品工业包装容器生产商应在其生产条件下，使用与生产用树脂相同的商业批次，在其工业包装容器上进行萃取物测试，以确保测试结果能够代表韩国药品品牌将要验证的商业产品。

韩国食品药品安全部（KFDA）还要求对用于已注册韩国药品的药品初级包装容器提供特定的尺寸文件。韩国药品注册文件（相当于韩国新药申请文件）包含容器规格，具体内容包括：标称容积及液位标记位置、瓶颈外径和内径及其公差、瓶盖拧紧扭矩规格、容器材料标识（树脂类型、等级、韩国食品药品安全部认可清单状态）以及颜色（透明、天然高密度聚乙烯、如有需要，着色高密度聚乙烯）。任何容器规格的变更——包括树脂批次变更、生产设备变更或腔体数量变更——均需向韩国食品药品安全部提交容器变更通知，并可能需要根据变更性质进行重新验证测试。

关键容器格式要求

3. HDPE 医药用 IBM 容器：规格和尺寸

HDPE是韩国医药包装箱的主要材料，占韩国医药包装箱HDPE初级容器产量的大部分。完整的医药HDPE包装箱指南包含在内。 HDPE IBM 加工指南本节重点介绍每种 HDPE IBM 容器规格的医药特定要求。

10毫升眼科用药瓶——韩国制药IBM销量领先者

Korean 10 ml HDPE ophthalmic containers are the highest-volume pharmaceutical IBM format in Korea — the combination of Korean ophthalmic prescription volume (Korea has one of East Asia’s highest rates of ophthalmic prescription per capita, driven by Korean contact lens use and Korean digital eye fatigue), Korean OTC artificial tear market and Korean pharmaceutical export requirements produces annual Korean ophthalmic container volume above 500 million units. IBM is the process of record for Korean ophthalmic containers because the dropper tip’s aperture, the dropper cap thread engagement and the container body’s sufficient transparency for fill-level inspection all require IBM’s precision that EBM cannot match. HDPE grade for Korean ophthalmic IBM: MI 0.3–0.5, density 0.950–0.960, pharmaceutical-grade additive package per KFDA positive list. Wall thickness: body 0.30–0.40 mm (sufficient transparency for fill-level check), neck 0.9–1.2 mm (closure retention). Production: Korea Ever-Power ZQ80 (20 cavities → ~15,800/hour) and ZQ110 (24 cavities → ~19,000/hour) are the principal Korean ophthalmic IBM platforms.

30毫升口服液小瓶

Korean 30 ml HDPE oral liquid vials serve unit-dose liquid medications — Korean syrups for paediatric use, Korean liquid vitamin preparations and Korean oral rehydration solutions. These formats require IBM for two specific reasons: the induction seal compatibility of the neck’s flat sealing surface (IBM’s injection mould produces the flat sealing land with Ra ≤ 0.05 μm required for consistent induction seal bonding across all 18–20 cavities) and the fill-level transparency of the HDPE body. At 30 ml, the IBM machine produces 18 cavities on the ZQ80 (approximately 16,200 vials per hour) or up to 22 cavities on the ZQ110 (approximately 19,800 vials per hour) — output rates that match Korean oral liquid pharmaceutical production line speeds without requiring multiple IBM machines for a single product line.

100毫升CRC药瓶

Korean CRC medicine bottles in HDPE at 100 ml are the most demanding pharmaceutical IBM format from a dimensional tolerance perspective. Korean KS M ISO 8317 child-resistant closure testing requires that less than 20% of adult test subjects fail to open the container within 5 minutes (CRC must be child-resistant but adult-accessible). This functional balance is achieved by the CRC cap’s mechanical engagement with the bottle neck’s engagement bead — an engagement that depends on the bead OD being within ±0.06 mm of the CRC cap’s designed engagement diameter. IBM’s ±0.05 mm neck OD tolerance is within this requirement; EBM’s ±0.15–0.25 mm tolerance is not. HDPE grade for CRC IBM: MI 0.5–0.8 for a stiffer bead that resists deformation under CRC cap push-down force; density 0.955–0.965 for maximum bead stiffness at the engagement contact zone.

4. PP 制药用 IBM 容器：当需要使用 PP 而非 HDPE 时

Polypropylene (PP) is required over HDPE for Korean pharmaceutical IBM containers in two well-defined application categories: terminal steam sterilisation (autoclave) and high-temperature pharmaceutical processes. PP’s heat deflection temperature (110–120°C at 0.45 MPa) allows it to retain dimensional integrity through Korean standard autoclave cycles at 121°C for 20 minutes, whereas HDPE begins to deform above 80–85°C under steam pressure and closure torque.

韩国产可高温高压灭菌PP IBM容器

Korean terminally sterilised pharmaceutical products — including some Korean ophthalmic preparations, Korean irrigating solutions and Korean topical pharmaceutical formulations — require primary containers that survive the autoclave cycle without dimensional change at the closure engagement zone. PP IBM containers for Korean autoclave use specify: PP copolymer grade (homopolymer PP has better heat resistance but is more brittle; random copolymer PP offers better clarity and impact resistance at a slight reduction in heat resistance — for Korean pharmaceutical autoclave at 121°C, either grade is adequate); melt flow rate 5–15 g/10min at 230°C/2.16 kg (higher MFR than HDPE IBM grades, matching PP’s typically higher flowability); barrel temperature 200–240°C on Korea Ever-Power ZQ series machines (higher than HDPE processing, requiring barrel zone setpoints adjusted from the HDPE baseline); dimensional verification post-autoclave (container neck OD and thread dimensions must be within specification after 3 autoclave cycles at 121°C/20 min — this post-autoclave dimensional verification is a KFDA qualification requirement for terminally sterilised Korean pharmaceutical containers).

PP 与 HDPE 在 IBM ZQ 系列机器上的加工差异

5. IBM 精密颈部设计，适用于制药封口

Pharmaceutical closure function is the most demanding test of IBM neck precision. Every Korean pharmaceutical closure system — CRC caps, dropper tips, induction seals, pump collars and spray actuators — specifies dimensional requirements for the container neck that the closure interacts with. IBM’s ±0.05 mm neck OD tolerance is the process characteristic that allows Korean pharmaceutical IBM containers to pass closure function tests across all cavities simultaneously, at production sampling frequencies, without statistical outliers at the tolerance edges.

韩国制药公司 IBM 的 CRC 颈部要求

Korean CRC containers must pass Korean KS M ISO 8317 child-resistant effectiveness testing — a formal protocol where 200 adult test subjects and 200 child test subjects each attempt to open the container under specified conditions. The mechanical function of the push-and-turn CRC cap depends on its ratchet teeth engaging the neck bead at a specific interference fit: too wide (neck OD too high) and the cap cannot be rotated — adult accessibility fails; too narrow (neck OD too low) and the cap can be rotated without depression — child resistance fails. The tolerance window for the neck engagement bead OD in Korean pharmaceutical CRC containers is typically ±0.06 mm from the CRC cap manufacturer’s specified nominal. IBM’s ±0.05 mm neck OD is within this window; EBM’s ±0.15–0.25 mm exceeds it. At 24-cavity production on a ZQ110, all 24 cavities must individually produce neck OD within the ±0.06 mm window on every cycle — a requirement that IBM meets through its injection-moulded neck insert precision, which holds the neck OD regardless of blow air pressure, cycle time variation or mould cooling variation.

滴管尖端和感应密封颈部的要求

Korean ophthalmic dropper caps use a snap-fit aperture control insert that seats inside the bottle neck bore, with the insert’s outer diameter engaging the bore inner surface at a specific interference. IBM’s injection mould core rod defines the bore inner diameter with ±0.04 mm tolerance — directly translating to ±0.04 mm aperture control insert fit variation. For Korean induction seal containers (30 ml oral liquid, 100 ml multi-dose liquid), the neck’s flat sealing land must be flat within 0.1 mm TIR (total indicator runout) for the induction foil to bond uniformly without gaps. IBM’s injection mould produces the sealing land surface with the same precision as a machined engineering component — flatness ±0.05 mm TIR across all cavities — because the sealing land is formed by the injection mould face rather than by a parting line or pinch-off as in EBM.

6. IBM在韩国制药洁净室环境中的应用

Korean pharmaceutical primary container production is increasingly conducted in ISO Class 8 or better cleanroom environments — particularly for ophthalmic containers, injectable primary packaging, and multi-dose liquid containers where particulate contamination in the container before filling is a KFDA pharmaceutical quality risk. IBM’s zero-flash production is a direct cleanroom compliance advantage because the particle generation mechanisms inherent to EBM — the flash trim station’s mechanical cutting, the flash removal conveyor, and the regrind system — are entirely absent from an IBM production cell.

Korean pharmaceutical cleanroom IBM cell design requirements for ISO Class 8 (equivalent to Korean GMP Grade D) container production: the IBM machine’s mould area — where containers are formed and where the output conveyor receives the containers — should be enclosed under HEPA-filtered positive-pressure supply air at a minimum of 0.45 m/s face velocity and 20 air changes per hour. Korea Ever-Power’s ZQ series machines accommodate HEPA enclosure installation by the Korean customer’s HVAC engineering team, with connection points for supply air ductwork identified in the ZQ machine layout drawings provided at order. The IBM machine’s hydraulic system should be filled with pharmaceutical-compatible food-grade hydraulic oil (specified as an option on ZQ80, ZQ110 and ZQ135) to prevent non-compliant mineral oil contamination if any hydraulic system seepage occurs in the cleanroom environment.

Korea Ever-Power’s dual hydraulic system (standard on the ZQ80 and above) provides a secondary cleanroom benefit: its 20–30% energy saving versus single-circuit competitor IBM machines reduces the waste heat load generated per unit of container output in the cleanroom space, which reduces the HVAC cooling demand required to maintain the cleanroom temperature set point (typically 20–22°C for Korean pharmaceutical cleanrooms). For Korean pharmaceutical factories where cleanroom HVAC energy is a significant operating cost, the ZQ80 and above models’ dual hydraulic energy efficiency contributes to reduced HVAC loads per unit of production output — a compounding benefit on top of the direct machine energy saving.

7. 韩国制药用IBM容器的GMP认证文件

韩国制药公司对IBM包装容器的认证遵循一套结构化的文档流程，这是韩国制药品牌对其IBM包装容器供应商的要求。了解这一流程有助于韩国IBM包装生产商提前准备正确的文档，从而缩短认证时间，避免因缺少技术数据而导致向韩国食品药品监督管理局（KFDA）提交申请的延误。

8. 韩国制药生产中IBM机器的选择

韩国制药行业的IBM机器选型与其他IBM应用一样，遵循相同的年产量框架，但制药生产需要考虑一个特殊因素：韩国GMP供应商资质认证要求在特定机器（通过机器序列号识别）和腔数下进行。初始认证后，如果更换为更高腔数的机器，则需要重新认证——考虑到成本和时间成本，对于制药行业的IBM机器而言，初始选择合适的规模比家用化学品行业的IBM机器更为重要，因为家用化学品行业的机器规格灵活性更高，重新认证的要求也更低。

韩国制药企业IBM规模化扩张的再认证策略： Korean pharmaceutical IBM producers who anticipate scale-up from ZQ60 to ZQ80 within 3 years should consider qualifying both machines simultaneously at initial installation — qualifying the ZQ60 as the primary production machine and the ZQ80 as the approved secondary machine in the same Korean KFDA container change notification. This pre-emptive dual-machine qualification adds modest documentation cost at initial qualification but avoids the 3–6 month Korean KFDA review period for the machine change notification when the scale-up occurs. Korea Ever-Power’s pharmaceutical application team advises Korean pharmaceutical IBM customers on dual-machine qualification strategy as part of the pre-purchase application consultation for pharmaceutical production lines.

常见问题解答

相关资源